Top Markets
Coin of the day
Heidelberg Pharma AG Heidelberg Pharma AG

Heidelberg Pharma AG

HPHA
株式のランク #20135
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a... Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
株価
$2.99
時価総額
$139.84M
変化(1日)
-0.40%
変化(1年)
-41.27%
DE
取引 Heidelberg Pharma AG (HPHA)

カテゴリー

Heidelberg Pharma AG(HPHA)の株価履歴
終値の最高値: $2.99 (2026-08-01)

終値の最安値: $68.95 (2006-11-01)
Heidelberg Pharma AG の株価履歴(2006 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) 8.96%
2025 24.78%
2024 -34.62%
2023 -35.99%
2022 6.20%
2021 -25.03%
2020 214.32%
2019 -21.18%
2018 -12.11%
2017 65.41%
2016 10.32%
2015 -15.82%
2014 -69.90%
2013 54.37%
2012 -75.41%
2011 -18.87%
2010 8.30%
2009 41.38%
2008 -53.24%
2007 -52.21%
2006 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$553.09 42.20%
US
$1.02K 50.56%
NL
$158.64 525.80%
US
$122.47 -12.71%
AU
$772.27 8.67%
CH